Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden. Issue 9 (22nd May 2020)

• Record Type: Journal Article
• Authors: Persson, Sofie; Johansen, Pierre; Andersson, Emelie; Lindgren, Peter; Thielke, Desirée; Thorsted, Brian L.; Jendle, Johan; Steen Carlsson, Katarina
• Is Part Of: Diabetes, obesity & metabolism. Volume 22:Issue 9(2020)
• Page Start: 1586
• Page End: 1597
• Publication Date: 2020-05-22
• Subjects: costs and cost analysis -- days absent from work -- diabetes complications -- diabetes mellitus -- disability -- insurance -- longitudinal register data -- sick leave -- type 2; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.14070
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract: Aims: To analyse days absent from work related to individual microvascular, macrovascular and other complications of type 2 diabetes (T2D) and to identify key drivers of absence. Materials and methods: National health and socio‐economic individual‐level data were analysed for the years 1997 to 2016 for people with T2D, and age‐, sex‐ and residential region‐matched controls (5:1) using linkage to Swedish national administrative registers, based on personal identity numbers. Regression analyses accounting for individual‐level clustering and education were estimated to obtain days absent by individual complications. Alternative analyses, for example, workforce indicator and age subgroups, were explored for robustness and comparison purposes. Results: A total of 413 000 people with T2D aged <66 years, comprising 4.9 million person‐years, was included. The crude proportion with any absence was higher among those with T2D compared to controls (47% vs. 26%) in the index year, and the median (IQR) number of days was higher (223 [77;359] vs. 196 [59;352]) if any absence. Regression analyses showed that complications per se were a key driver of days absent: stroke (+102 days); end‐stage renal disease (+70 days); severe vision loss (+56 days); and angina pectoris, heart failure, and osteoarthritis (+53 days each). The alternative analyses showed similar levels of days absent and age subgroups differed in expected directions. Conclusions: This study provides evidence of the persisting impact on productivity from complications that supports continued efforts to reduce risk factors in T2D. Future studies on burden of disease and economic evaluations of new therapies and disease management may use this new set of complication‐specific estimates to improve understanding of the value of reducing complications.